Eisai continues to experience growth in the United States, where we are headquartered in Woodcliff Lake, New Jersey. In addition to our headquarters operation, we also house commercial and clinical development organizations at this site.
This location is supported by two global demand chain organizations in Baltimore, Maryland and Raleigh, North Carolina. We also operate two Eisai discovery labs, one in Exton, Pennsylvania and in Cambridge, Massachusetts.
The Eisai Center for Genetics Guided Dementia Discovery (G2D2) is an exploratory research facility in Cambridge, MA, that seeks to leverage the power of human genetics, data sciences and precision chemistry to develop compounds to treat Alzheimer’s disease (AD) and other dementias. At G2D2, our diverse group of passionate, dedicated and collaborative scientists not only focus on how data can help identify and validate therapeutic targets, but also how it guides novel approaches to drug targets and aims to match them to the right patient at the right time. Through its four research segments (Data Sciences, Discovery Sciences, Precision Chemistry and Immunodementia*), the team at G2D2 is uniquely positioned to deliver tailor-designed small molecules, anti-sense oligo-nucleotides, and other solutions for targeted therapeutics. Following through on our entrepreneurial mindset, G2D2 established the Eisai Incubator for NeuroDiscovery (e-IND), which provides space to Cambridge-based start-up/spin-out companies conducting high-risk but potentially transformative research that can impact the discovery of breakthrough neuroscience therapeutics.
*Immunodementia is a novel genetically validated target modulating immune mechanism that treats dementia.